
Purple Yam Extract (*Dioscorea Alata L.*) As Adjuvant Antihypertension Medicine for Postpartum Hypertension

Dina Hanifa*, Suharyo Hadisaputro, Supriyana, Bedjo Santoso

Politeknik Kesehatan Kemenkes Semarang

* hanifadina01@gmail.com

ABSTRACT

One third of women who have hypertension in pregnancy will continue to have high blood pressure during the postpartum period. Postpartum hypertension has effects such as cardiovascular disorders to HELLP syndrome. Potential adjuvant pharmacological therapy is needed, one of them is purple yam extract which contains flavonoids and dioscorin to reduce blood pressure. This type of research is a quasi experiment with pre-post test with control group design. The research respondents consisted of 16 people treated with purple yam extract 320 mg/day and nifedipine 10 mg/day and 16 people were given nifedipin 10 mg/day for 14 days. The results of the study were the systolic blood pressure of the intervention group decreased by 28.12 mmHg and the control group decreased by 8.94 mmHg with a p-value of 0,000. The diastolic blood pressure of the intervention group decreased by 18.43 mmHg and the control group decreased by 3.75 mmHg with a p-value of 0,000. The conclusion of this study is purple yam extract has the potential as an alternative therapy to reduce blood pressure in postpartum hypertension.

Keywords : Purple Yam Extract, Blood Pressure, Hypertension, Postpartum

Received June 10, 2020; Revised June 28, 2020; Accepted August 14, 2020



STRADA Jurnal Ilmiah Kesehatan, its website, and the articles published there in are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

BACKGROUND

One third of women who have hypertension in pregnancy or pre-eclampsia will continue to have high blood pressure during the postpartum period even have a normal blood pressure in early labor (Smith, Waugh and Nelson-piercy, 2013). Postpartum hypertension has effects such as hypofibrinogemia, cardiovascular disorders, liver necrosis, pulmonary edema, brain hemorrhage, acute kidney injury, HELLP syndrome (*Hemolysis Elevated Liver enzyme Low Platelet count*) (Ghuman et al., 2009), (Smith, Waugh and Nelson-piercy, 2013), (Nzeli et al., 2017).

The World Health Organization states the number of maternal deaths as many as 295,000 women caused by hypertension came second at 14% after bleeding 27.1% (Say et al., 2006). Likewise with the trend of the causes of MMR in Indonesia has experienced a shift with increasing cases of pregnancy hypertension and postpartum hypertension from year to year (Kemenkes RI, 2018).

Handling of maternal postpartum hypertension aims to prevent complications can occur through pharmacological and non-pharmacological treatment. Pharmacological treatment that is often used by health workers is the administration of nifedipine 10 mg. Some patients also require combination pharmacological therapy for hypertension so that they can achieve normal blood pressure targets, but combination therapy can increase treatment costs and reduce patient compliance due to the large amount of drugs that must be consumed (Ismalia et al., 2016).

Therefore non-pharmacological therapy is needed as an adjuvant to antihypertensive drugs to reduce blood pressure, one of which is the provision of purple yam extract (*Dioscorea alata L.*) which contains bioactive compounds namely dioscorin and flavonoids which have activities as antihypertensive and antioxidants that work to inhibits ACE (*Angiotensin Converting Enzym*) (Prasetya et al., 2016). Some studies also show that dioscorin can reduce blood pressure or antihypertensive effects both in vivo and in vitro (Liu et al., 2009a). Dioscorin in certain doses has the effectiveness in inhibiting angiotensin-converting enzyme (ACE) up to 50% when compared to captopril which is a standard drug for hypertension (Hsu et al., 2002).

Based on the above background, the effect of purple yam has a role in reducing blood pressure so that the potential of purple yam extract (*Dioscorea alata L.*) as an adjuvant to antihypertensive drugs to change blood pressure in postpartum hypertensive mothers.

METHODS

This research uses Quasi Experiment research with pre and post test with control group design. This study aims to analyze the potential of purple yam extract (*Dioscorea alata L.*) as an alternative therapy for reducing blood pressure in postpartum hypertension. The sample consisted of 16 intervention groups and 16 control groups. Each group was given the intervention for 14 days. The intervention group was given purple yam extract (a daily dose of 320 mg) plus nifedipine (a daily dose of 10 mg), while the control group was only given nifedipine with a daily dose of 10 mg. Blood pressure were measured everyday from pretest until posttest. The instrument used for primary blood pressure data collection is the observation sheet. Data were analyzed by means of the Independent T test parametric test to determine differences between groups on systolic and diastolic blood pressure variables.

RESULTS**Univariate analysis****Tabel 1. Distribution of Characteristics of Respondents by Age, Parity, Type of Labor, History Hypertension in Pregnancy, Family History and Stress Level**

Characteristics	Intervention Group (n=16)		Control Group (n=16)		<i>*p</i>
	N	%	N	%	
Age					0,504
≤ 20	-	-	-	-	
21-35	13	81,3	8	50	
>35	3	18,8	8	50	
Parity					0,629
Primipara	8	50	7	43,8	
Multipara	8	50	9	56,3	
Grandemultipara	-	-	-	-	
Type of Labor					0,686
Normal Birth	10	62,5	5	31,3	
SC	6	37,5	11	68,8	
History in Pregnancy					0,084
There	8	50	9	56,3	
Nothing	8	50	7	43,8	
Family History					0,408
There	5	31,3	5	31,3	
Nothing	11	68,8	11	68,8	
Stress Level					0,697
Normal	12	75	11	68,8	
Mild	3	18,8	4	25	
Moderate	1	6,3	1	6,3	
Severe	-	-	-	-	
Extremely severe	-	-	-	-	

*Homogeneity

Table 1 shows frequency distribution of respondents. The age variable describes the highest age at the age of 21-35 is 13 respondents (81.3%) in the intervention group, while the control group has the same number at the age 21-35 and >35 years age groups that is 8 respondents (50%). The parity variable describes respondents with the same number of birth categories of 8 respondents (50%) primipara and 8 respondents (50%) multiparara in the intervention group, while in the control group most of the respondents had the category of multipara births namely 9 respondents (56.3%).

The type of labor level variable shows the highest type is normal birth of 10 respondents (62.6%) in the intervention group and in the control group most of the SC is 11 respondents (68.8%). The pregnancy history variable shows the highest respondents in the intervention group there were respondents with a history of pregnancy hypertension as many as 8 respondents (50%) and 8 respondents with no history of pregnancy, whereas in the control group most of the respondents had a history of pregnancy hypertension that was 9 respondents (56.3%). The family hypertension history variables describe the highest of respondents there is no family history of hypertension, namely 11 respondents (68.8%) in the each group. The stress level variable most of the respondents had normal stress

levels, namely 12 respondents (75%) in the intervention group and 11 respondents (68.8%) in the control group.

Bivariate Analysis Systolic

Tabel 2. Differences in Systolic Blood Pressure Values Between The Intervention and Control Group

Systolic Blood Pressure	Mean±SD		p-value
	Intervension	Control	
Pre test	149,81±5,822	149,50±6,623	0,888
Post test 1	149,44±5,727	149,25±6,061	0,929
Post test 2	147,94±6,038	149,06±7,028	0,631
Post test 3	145,00±6,282	148,25±5,615	0,133
Post test 4	143,44±4,885	148,19±5,879	0,019
Post test 5	141,13±5,608	147,50±6,066	0,004
Post test 6	140,81±6,134	147,38±7,108	0,009
Post test 7	136,94±7,767	146,38±6,927	0,001
Post test 8	134,13±8,049	145,81±6,167	0,000
Post test 9	131,75±7,672	145,69±5,301	0,000
Post test 10	129,00±8,140	145,44±6,683	0,000
Post test 11	127,69±7,436	145,06±7,602	0,000
Post test 12	126,31±7,427	144,94±6,465	0,000
Post test 13	125,06±6,875	144,13±7,676	0,000
Post test 14	122,44±7,780	142,56±6,449	0,000
Post test 15	121,69±7,245	140,56±5,796	0,000
Δ Pre-Post 15	28,12±8,205	8,94±7,945	0,000

* Independent T-test

Based on table 2, the results of the Independent T-test statistical test showed a p-value <0.05 on the day 4 measurement (p-value = 0.019 <0.05), meaning that there were significant differences between changes systolic blood pressure in intervention groups and control group. However, the results showed that on the day 7 the systolic blood pressure clinically was effective, because blood pressure was starting at <140 mmHg.

Bivariate Analysis Diastolic

Tabel 3. Differences in Diastolic Blood Pressure Values Between The Intervention and Control Group

Diastolic Blood Pressure	Mean±SD		p-value
	Intervension	Control	
Pre test	95,31±2,960	95,50±2,852	0,856
Post test 1	94,44±3,245	94,50±2,852	0,333
Post test 2	93,88±3,631	94,06±3,172	0,877
Post test 3	93,00±3,795	94,00±3,688	0,456
Post test 4	91,81±3,692	94,00±4,033	0,120
Post test 5	90,06±3,660	93,94±3,549	0,005
Post test 6	89,19±4,037	93,94±3,549	0,001
Post test 7	88,13±4,455	93,69±3,877	0,001
Post test 8	86,94±4,404	93,69±3,877	0,000

Post test 9	85,69±4,483	93,63±2,802	0,000
Post test 10	84,13±4,588	93,50±3,204	0,000
Post test 11	82,88±4,272	93,44±3,651	0,000
Post test 12	81,81±4,888	92,50±3,386	0,000
Post test 13	81,81±4,888	92,50±3,386	0,000
Post test 14	76,88±6,065	91,75±4,851	0,000
Post test 15	76,88±6,065	91,75±4,851	0,000
Δ Pre-Post 15	18,44±6,408	3,75±5,222	0,000

* Independent T-test

Based on table 3, the results of the Independent T-test statistical test showed a p-value <0.05 on the day 5 measurement (p-value = 0.005 <0.05), meaning that there were significant differences between changes diastolic blood pressure in groups intervention and control group. However, the results showed that on the day 6 that diastolic blood pressure clinically was effective, because blood pressure was starting at <90 mmHg.

DISCUSSION

The results of the analysis of differences in changes in systolic and diastolic blood pressure in the intervention group and the control group can be seen in Tables 2 and 3, which are the most systolic and diastolic blood pressure decreased in the intervention group, namely systolic 28.12 mmHg and diastolic 18.44 mmHg. Whereas the control group was decrease in systolic 8.94 mmHg and diastolic 3.75 mmHg. The mean difference in systolic blood pressure between the intervention and control groups was 19.18 mmHg with a p-value of 0,000. While the diastolic blood pressure mean difference between the intervention and control groups was 14.69 mmHg with a p-value of 0,000.

The results of blood pressure analysis obtained are supported by research conducted by the *Fourth Internal Medicine Department* on calcium channel blockers having minimal metabolic effects. Symptoms in postpartum hypertensive mothers who consume nifedipine are usually mild, including dizziness, nausea, redness of the skin, headaches and palpitations. A more serious but rare effect is hypotension (Burnier, 2017).

The National Center of Complementary and Alternative Medicine of the National Institute of Health classifies various kinds of treatment and therapy systems into 5 categories, one of which is Biological Base Therapies (BBT) which is a type of complementary therapy using natural ingredients. The use of natural ingredients as traditional medicine can be a supporting alternative with fewer side effects compared to the available drugs (Sharma et al., 2017).

The use of alternative drugs needs to be considered given the side effects that can be caused in consuming nifedipine. One of them by using purple yam extract. Purple yam is one of the local plants in Indonesia. Purple yam is included in the *Dioscorea* family, which is a hypotensive agent for flavonoids and dioscorin.

Flavonoids function to protect endothelial function and help reduce blood pressure through the effects of hypotension by inhibiting the activity of ACE and as a diuretic. Flavonoids inhibit the action of ACE which plays an important role in the change of angiotensin I to angiotensin II as a cause of narrowing of blood vessels and raising blood pressure (Nadila, 2014). Dioscorin also has the ability to inhibit angiotensin converting enzyme (ACE) which triggers an increase in blood pressure (Hsu et al, 2002; Liu et al, 2009b). Purple yam extract that given to postpartum hypertension in the study contained 1222,731 mg/100 gram flavonoids and 33.817% dioscorin.

Various studies on the benefits of purple yam (*Dioscorea alata* L.) have been carried out, but only a few have examined the relationship with hypertension, several studies mentioned include studies conducted by Liu et al (2009), studies on mice models of hypertensive given water purple yam extracts and purple yam powders once a day using a sonde for 1 month. Administration of 40 mg/Kg powder extract showed a 32.4 mmHg systolic reduction and a diastolic reduction of 31.9 mmHg at 6-8 hours after administration (Liu et al., 2009a).

The results of the bivariate analysis of the study stated that the pharmacological therapy of nifedipine 10 mg and purple yam extracts 320 mg as an adjuvant had a higher potential effect than the pharmacological therapy of nifedipine 10 mg in reducing systolic and diastolic blood pressure in postpartum hypertension. Purple yam extract in this study acts as a potentiation with nifedipine given together with different actions, but has a greater effect on patients if given together rather than each effect separately.

CONCLUSION

The providing of purple yam extract (*Dioscorea Alata* L.) dose 320 mg for 14 days in postpartum hypertension who get nifedipine 10 mg/day has the potential adjuvant to decreasing systolic and diastolic blood pressure.

This research can be used as a reference regarding nonpharmacological therapy accompanying antihypertensive drugs to help reduce maternal blood pressure in postpartum period and the development of midwifery to improve the quality of providing midwifery care in post natal care midwifery services.

REFERENCE

- Burnier, M. (2017). Drug adherence in hypertension. *Pharmacological Research*, 125, 142–149.
- Ghuman, N., Rheiner, J., Tendler, B. E., & White, W. B. (2009). Hypertension in the Postpartum Woman: Clinical Update for the Hypertension Specialist. *The Journal of Clinical Hypertension*, 11(12), 726–733.
- Hsu, F. H., Y. H. Lin, M. H. Lee, C. L. Lin, and W. C. Hou. (2002). Both Dioscorin, The Tuber Storage Protein of Yam (*Dioscorea alata* CV Tainong No. 1), and its Peptic Hydrolysates Exhibited Angiotensin Converting Enzyme Inhibitory Activities. *J. Agric.Food Chem*, 50, 6109-6113.
- Ismalia N, Zuraida R. (2016). Effect Tomato (*Lycopersion esculentum* Mill) for Decreasing High Blood Pressure. *MAJORITY*, 5(4), 107-111.
- Kementrian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia 2017. (2018). Jakarta: Kementerian Kesehatan Republik Indonesia.
- Liu, Y.H., Lin, Y.-S., Liu, D.-Z., Han, C.-H., Chen, C.-T., Fan, M., & Hou, W.-C. (2009a). Effects of Different Types of Yam (*Dioscorea alata*) Products on the Blood Pressure of Spontaneously Hypertensive Rats. *Bioscience, Biotechnology, and Biochemistry*, 73(6), 1371–1376.
- Liu, Y. M. and K. W. Lin. (2009b). Antioxidative ability, dioscorin stability, and the quality of yam chips from various yam species as affected by processing method. *Journal of Food Science*, 74(2), C118-C125.
- Nadila F. (2014). Antihypertensive Potential of Chayote Fruit Extract for

Hypertension Treatment. J Majority, 3(7), 34-38.

Nzelu, D. (2018). Dumitrascu-Biris, D., Hunt, K. F., Cordina, M., & Kametas, N. A. Pregnancy outcomes in women with previous gestational hypertension: A cohort study to guide counselling and management. *Pregnancy Hypertension*, 12, 194–200.

Prasetya, Estiasih Teti, Nugrahini Nur Ida Panca. (2016). Potensi Tepung Ubi Kelapa Ungu dan Kuning. *Jurnal Pangan dan Agroindustri*, 4(2), 468-473.

Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels JD, et al. (2014). Global Causes of Maternal Death: A WHO Systematic Analysis. *Lancet Global Health*, 2(6), e323-e333.

Sharma KJ GN. (2017). Oral Labetalol Compared to Oral Nifedipin for Postpartum Hypertension: A randomized controlled trial. *Hypertension in Pragnancy*, 36(1), 44-47.

Smith, M., Waugh, J., & Nelson-Piercy, C. (2013). Management of postpartum hypertension. *The Obstetrician & Gynaecologist*. 15(1), 45–50.